Department of Health and Human Services Food and Drug Administration DMETS Evaluation of Proprietary Names Jerry Phillips, RPh Associate Director Office.

Slides:

Advertisements

Similar presentations

Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.

Advertisements

FDA REGULATION: EFFECT ON PAIN MANAGEMENT IN THE ED RICHARD R. ABOOD, R.Ph., J.D. Professor Pharmacy Practice University of the Pacific RICHARD R. ABOOD,

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Regulatory.

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

Development and Review Process of NDA, ANDA/AADA and OTC Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Associate Professor Department of Pharmaceutics KLE.

Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.

+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.

Oncology Pediatric Initiatives Richard Pazdur, MD Director, Division of Oncology Drug Products.

Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.

Investigational New Drug Application 21 CFR Part 312 A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International

Regulation of Generic Drugs Office of Generic Drugs Craig Kiester Regulatory Support Branch.

Joint NDAC/PAC meeting October 18, 2007 OTC Cold and Cough Products: Use in Children Advisory Committee Meeting October 18, 2007 Joel Schiffenbauer, MD.

Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.

Proprietary Names and the Drug Approval Process John K. Jenkins, M.D., F.C.C.P. Director, Officer of New Drugs Center for Drug Evaluation and Research.

Proprietary Name Testing Using “Prescription Analysis Studies” Thomas H. Hassall, MS Director, Global Regulatory Policy Merck Research Laboratories.

1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.

Career Opportunities in Statistics John Borkowski Montana State University Panel Discussion Pattaya Conference on Statistics Pattaya, Thailand.

Stages of drug development

1 Regulatory Concepts for Dual Indication Combination Products Charu Mullick, M.D. Division of Antiviral Products, CDER U.S. Food and Drug Administration.

CVM’s Procedure for Setting Tolerances

Prof. Moustafa M. Mohamed Vice dean Faculty of Allied Medical Science Pharos University in Alexandria Development and Regulation of Medical Products (MEDR-101)

CASTRO VALLEY ADULT AND CAREER EDUCATION CMA PROGRAM FOOD AND DRUG ADMINISTRATION.

Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.

Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.

1 Safety Pharmacology for Oncology Pharmaceuticals at CDER John K. Leighton Associate Director for Pharmacology CDER/OND/OODP.

A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication A substance used in the diagnosis, treatment,

Application of Safety Principles to Labeling, Packaging and Nomenclature Decisions Michael R. Cohen, RPh, MS, ScD, FASHP Institute for Safe Medication.

Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention February 2003.

ICH V1 An FDA Update Min Chen, M.S., RPh Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.

Abuse Liability and Drug Scheduling: The Role of the FDA Deborah B

Using AERS in Postmarketing Surveillance of Medication Errors Carol Holquist, RPh Director, Division of Medication Errors and Technical Support Office.

Development and Regulation of Medical Products (MEDR-101)

PROPRIETARY NAME EVALUATION AT FDA Jerry Phillips, RPh Associate Director for Medication Error Prevention Office of Drug Safety December 4, 2003.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research.

PATRICIA KERBY, MPA HUMAN SUBJECTIONS PROTECTION COMPLIANCE OFFICER OFFICE OF RESEARCH COMPLIANCE What are the FDA’s expectations in 2010?

Communication of Drug Safety Information Food and Drug Administration Center for Drug Evaluation & Research Public Hearing December 8, 2005.

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

1 One Year Post Exclusivity Adverse Event Review: Carboplatin Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

1/33.  What is INDA ?  Types of INDAs  Objectives of INDAs  Format & Contents of an INDA  IND Safety reports  IND Annual Reports  IND Review Process.

The New Drug Development Process (www. fda. gov/cder/handbook/develop

The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.

History of Pediatric Labeling

Screening Proprietary Drug Names for Similarities: Research Design and Questionnaire Structure. Shari Diamond, J.D., Ph.D. Northwestern University June.

FDAAA – Report on DTC Advertising Kristin Davis, J.D. Deputy Director, Division of Drug Marketing, Advertising, and Communications Office of Medical Policy,

FDA Office of Orphan Products Development

Cardiovascular Health Research Unit, Seattle, WA IOM recommendations on drug safety: relevance for vaccines? Bruce M Psaty, MD, PhD.

Office of Drug Safety Updates Drug Safety and Risk Management Advisory Committee Meeting February 10, 2006 Gerald J. Dal Pan, MD, MHS Director, Office.

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

Government Agencies. World Health Organization  Sponsored by United Nations  Investigates serious diseases & health issues across the world.

Initiatives Drive Pediatric Drug Development January 30, 2002.

Drug Regulation, Development, Names, and Information Chapter 3 Copyright (c) 2004 Elsevier Inc. All rights reserved.

Suzanne Sechen, Ph.D. Leader, Ruminant Drugs Team Division of Production Drugs Office of New Animal Drug Evaluation, CVM Labeling Issues.

12/4/031 Drug Safety and Risk Management Advisory Committee Advancing the Science of Proprietary Drug Name Review Paul J. Seligman, MD.

The CDRH Software Message (October 19, 2002) John F Murray Jr.. Center for Devices & Radiological Health US Food and Drug Administration

미국의 마약류 관리제도 - FDA 와 NIDA 의 조직 및 업무 현황 의약품평가부 이선희.

Regulation of Generic Animal Drugs in the United States

1 Structured Product Labeling Project Update Randy Levin, M.D. Director for Health and Regulatory Data Standards Food and Drug Administration HL7 Working.

A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,

Clinical Trials.

Assuring Compliance with the JCAHO 2004 Standards: Medication Management Patricia C. Kienle, RPh, MPA, FASHP Medication Safety Manager Cardinal Health.

Version: 27 May 2007 New Models for Collaboration: Patients as Drivers and Partners in Neurological Research Integrating Patient Input Within the Drug.

Drug Development Process Stages involved in Regulating Drugs

Recent Evolution of New Drug Review and Approval System in Korea

Clinical Trials — A Closer Look

Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

HREC Operating Procedures for the Review of Low and Moderate to High Risk Projects

IND Review Process Seoul National University

Current Evaluation Process

Presentation transcript:

Department of Health and Human Services Food and Drug Administration DMETS Evaluation of Proprietary Names Jerry Phillips, RPh Associate Director Office of Drug Safety CDER June 26, 2003

Department of Health and Human Services Food and Drug Administration PRE-MARKETING EVALUATION Begin Review at the End of phase II of an IND and 90 days prior to approval of NDA Proprietary Name Analysis –Expert Panel Review –Verbal and Handwritten Rx studies –Computer-Assisted Analysis Labeling and Packaging Analysis –Container, Carton, Package Insert, and Proposed Packaging Configuration Overall Risk/Benefit Evaluation Written Recommendation provided to Division

Department of Health and Human Services Food and Drug Administration WHAT IS DMETS LOOKING FOR? Sound-alike/Look-alike: –To currently marketed drug names –To other Medicinal Products –To commonly used medical abbreviations, medical procedures, and/or lab tests

Department of Health and Human Services Food and Drug Administration Contributing Factors for Name Confusion Similar indications Same patient population Identical formulations Overlapping strengths or directions Stored in same areas

Product Sponsor Reviewing Division Project Manager Consult Requests Name Expert Panel RXSTUDY Name Studies Computer Analysis Safety Evaluators DMETS Team Leaders Deputy Division Dir Office of Drug Safety Recommendation Decision Made Project Manager Request for Proprietary Name Consult